NCT01708889View on ClinicalTrials.gov

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Chronic Hepatitis B Virus InfectionChronic Hepatitis C Virus Infection
Interventions
BIOLOGICAL

BMS-914143 (Peginterferon Lambda-1a)

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

37920

New Orleans Center For Clinical Research - Knoxville, Knoxville

33014-3616

Clinical Pharmacology Of Miami Inc., Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY